Opinion|Videos|January 15, 2026
Clinical Experience with Tocilizumab and Upadacitinib in GCA Treatment
Advertisement
Episodes in this series
This video covers the following questions:
- Please share your clinical experience with tocilizumab and upadacitinib.
- Let’s discuss treatment selection criteria for approved therapies. What patient subgroups would you consider for targeted agents, and what factors would contribute towards selecting one treatment over another?
Advertisement
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.
Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Mirikizumab Deep Remission in Crohn’s Disease, With Stefan Schreiber, MD
3
Reaching Comprehensive Disease Control in UC, With Stefan Schreiber, MD
4
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
5